3 Dividend Stocks to Buy in September for Passive Income Generation

153
23
Favorite

3 Dividend Stocks to Buy in September for Passive Income Generation

Motley Fool2022-09-02

Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

153

Report

Comment（23）

Tanyl
·2022-09-03
Buy Abbott in call option
Reply
1
Report
Yishun123
·2022-09-02
Like
Reply
Like
Report
ECSY88
·2022-09-02
[Smile]
Reply
Like
Report
Boo2020
·2022-09-02
K
Reply
2
Report
Boo2020
·2022-09-02
K
Reply
1
Report
JemLIm
·2022-09-02
Yes
Reply
2
Report
Dbw
·2022-09-02
Like
Reply
2
Report
Fold Replies
- Dbw:
  like
  2022-09-02
  Reply
  Report
sinneDteo
·2022-09-02
Good luck everyone
Reply
2
Report
Mm101
·2022-09-02
G
Reply
Like
Report
Mm101
·2022-09-02
C
Reply
Like
Report
Akyy12
·2022-09-02
Pls like
Reply
3
Report
YYKTAN
·2022-09-02
Pls like thanks
Reply
1
Report
YYKTAN
·2022-09-02
Latest
Reply
2
Report
Fold Replies
- Akyy12:
  K
  2022-09-02
  Reply
  Report
- JemLIm:
  cool
  2022-09-02
  Reply
  Report
- sinoob:
  Latest
  2022-09-02
  Reply
  Report
玉树临风英俊
·2022-09-02
👌
Reply
2
Report
Fold Replies
- atsc:
  Ok
  2022-09-02
  Reply
  Report
ycwoo
·2022-09-02
Great article! I would like to share it.
Reply
2
Report
jerwy
·2022-09-02
wow
Reply
1
Report
MrHuattt
·2022-09-02
Okau
Reply
1
Report
Mccoy
·2022-09-02
Thanks
Reply
Like
Report
JaneJane
·2022-09-02
👍🏻
Reply
6
Report
Fold Replies
- babiboo:
  ohh
  2022-09-02
  Reply
  Report
- jerwy:
  ok
  2022-09-02
  Reply
  Report
- 玉树临风英俊:
  Ok
  2022-09-02
  Reply
  Report
View more 1 comments
Tanyl
·2022-09-02
Buy Abbott in call option
Reply
7
Report
Fold Replies
- Stephanie712:
  Ok
  2022-09-02
  Reply
  Report
- HUATBIG:
  ok
  2022-09-02
  Reply
  Report

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2264296558?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-09-02 16:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2264296558","market":"us","top_or_hot":-1,"title":"3 Dividend Stocks to Buy in September for Passive Income Generation","media":"Motley Fool","content":"<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4566","symbol_name":"资本集团","start_time":0,"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","article_id":"2264296558","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","pubTimestamp":1662107204,"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4566":"资本集团","CVS":"西维斯健康","BK4568":"美国抗疫概念","BK4548":"巴美列捷福持仓","BK4535":"淡马锡持仓","ABT":"雅培","BK4551":"寇图资本持仓","ABBV":"艾伯维公司","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4581":"高盛持仓","BK4504":"桥水持仓"},"translate_title":"3 9月买股息股被动创收","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABBV":0.9,"ABT":0.9,"CVS":0.9},"content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","kind":null,"is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":9939788716,"gmtCreate":1662168257535,"gmtModify":1676537011112,"author":{"id":"4087109808120260","authorId":"4087109808120260","name":"Tanyl","avatar":"https://static.tigerbbs.com/174329973340cf0f5b68791ee5b08afd","vip":1,"crmLevel":9,"crmLevelSwitch":1,"idStr":"4087109808120260","authorIdStr":"4087109808120260"},"htmlText":"Buy Abbott in call option","listText":"Buy Abbott in call option","text":"Buy Abbott in call option","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939788716","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939222790,"gmtCreate":1662121385710,"gmtModify":1676537002329,"author":{"id":"4104549918133510","authorId":"4104549918133510","name":"Yishun123","avatar":"https://community-static.tradeup.com/news/e9d6b765232ac9af7a459ac04954fee4","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4104549918133510","authorIdStr":"4104549918133510"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939222790","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939226018,"gmtCreate":1662120753735,"gmtModify":1676537002269,"author":{"id":"4094208649095680","authorId":"4094208649095680","name":"ECSY88","avatar":"https://community-static.tradeup.com/news/2ca1c7b2466a90f08306b9efc33770f1","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4094208649095680","authorIdStr":"4094208649095680"},"htmlText":"[Smile]&nbsp;","listText":"[Smile]&nbsp;","text":"[Smile]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939226018","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939265841,"gmtCreate":1662118843383,"gmtModify":1676537001993,"author":{"id":"3572316669494636","authorId":"3572316669494636","name":"Boo2020","avatar":"https://static.tigerbbs.com/b9140860aa799166f7ff2aef054c4197","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3572316669494636","authorIdStr":"3572316669494636"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939265841","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939265110,"gmtCreate":1662118838030,"gmtModify":1676537001993,"author":{"id":"3572316669494636","authorId":"3572316669494636","name":"Boo2020","avatar":"https://static.tigerbbs.com/b9140860aa799166f7ff2aef054c4197","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3572316669494636","authorIdStr":"3572316669494636"},"htmlText":"K","listText":"K","text":"K","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939265110","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939261032,"gmtCreate":1662118058127,"gmtModify":1676537001820,"author":{"id":"3574813808924805","authorId":"3574813808924805","name":"JemLIm","avatar":"https://static.tigerbbs.com/ee9608155c1d123b0bf9fc773916aac7","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"3574813808924805","authorIdStr":"3574813808924805"},"htmlText":"Yes","listText":"Yes","text":"Yes","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939261032","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939263514,"gmtCreate":1662117956338,"gmtModify":1676537001812,"author":{"id":"3574901428369611","authorId":"3574901428369611","name":"Dbw","avatar":"https://static.tigerbbs.com/b2b540981c00cc0005e6241f782bd3c5","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":1,"crmLevelSwitch":0,"idStr":"3574901428369611","authorIdStr":"3574901428369611"},"htmlText":"Like","listText":"Like","text":"Like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9939263514","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":103735357,"gmtCreate":1662117963953,"gmtModify":1663258366260,"authorId":3574901428369611,"author":{"id":3574901428369611,"idStr":"3574901428369611","authorId":3574901428369611,"name":"Dbw","avatar":"https://static.tigerbbs.com/b2b540981c00cc0005e6241f782bd3c5","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9939263514,"type":1,"supId":0,"prevId":0,"content":"<u>like</u>","text":"<u>like</u>","html":"<u>like</u>"}],"langContent":"EN"},{"id":9939287940,"gmtCreate":1662116944480,"gmtModify":1676537001570,"author":{"id":"3574190598868333","authorId":"3574190598868333","name":"sinneDteo","avatar":"https://static.tigerbbs.com/120e946e020025a0f2a0ab36032d4712","vip":1,"crmLevel":7,"crmLevelSwitch":0,"idStr":"3574190598868333","authorIdStr":"3574190598868333"},"htmlText":"Good luck everyone&nbsp;","listText":"Good luck everyone&nbsp;","text":"Good luck everyone","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939287940","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939286130,"gmtCreate":1662116326920,"gmtModify":1676537001418,"author":{"id":"3565081661382277","authorId":"3565081661382277","name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3565081661382277","authorIdStr":"3565081661382277"},"htmlText":"G","listText":"G","text":"G","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939286130","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939286037,"gmtCreate":1662116311929,"gmtModify":1676537001411,"author":{"id":"3565081661382277","authorId":"3565081661382277","name":"Mm101","avatar":"https://static.tigerbbs.com/01758aa877d9e5a9767d24de3a4e2ff1","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3565081661382277","authorIdStr":"3565081661382277"},"htmlText":"C","listText":"C","text":"C","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939286037","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939288782,"gmtCreate":1662116298046,"gmtModify":1676537001409,"author":{"id":"4098595137500940","authorId":"4098595137500940","name":"Akyy12","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4098595137500940","authorIdStr":"4098595137500940"},"htmlText":"Pls like&nbsp;","listText":"Pls like&nbsp;","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939288782","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939289712,"gmtCreate":1662115719836,"gmtModify":1676537001283,"author":{"id":"3586858995147972","authorId":"3586858995147972","name":"YYKTAN","avatar":"https://static.tigerbbs.com/e9c7bf12299d79e1cacc0c24919b7a3c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3586858995147972","authorIdStr":"3586858995147972"},"htmlText":"Pls like thanks","listText":"Pls like thanks","text":"Pls like thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939289712","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939289278,"gmtCreate":1662115713694,"gmtModify":1676537001275,"author":{"id":"3586858995147972","authorId":"3586858995147972","name":"YYKTAN","avatar":"https://static.tigerbbs.com/e9c7bf12299d79e1cacc0c24919b7a3c","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3586858995147972","authorIdStr":"3586858995147972"},"htmlText":"Latest","listText":"Latest","text":"Latest","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":3,"repostSize":0,"link":"https://ttm.financial/post/9939289278","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":103734967,"gmtCreate":1662116348014,"gmtModify":1663258365640,"authorId":4098595137500940,"author":{"id":4098595137500940,"idStr":"4098595137500940","authorId":4098595137500940,"name":"Akyy12","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9939289278,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">K</span>","text":"<span class=\"s1\">K</span>","html":"<span class=\"s1\">K</span>"},{"id":103735377,"gmtCreate":1662118063316,"gmtModify":1663258364936,"authorId":3574813808924805,"author":{"id":3574813808924805,"idStr":"3574813808924805","authorId":3574813808924805,"name":"JemLIm","avatar":"https://static.tigerbbs.com/ee9608155c1d123b0bf9fc773916aac7","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.25","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9939289278,"type":1,"supId":103734967,"prevId":0,"content":"<u>cool</u>","text":"<u>cool</u>","html":"<u>cool</u>"},{"id":103734852,"gmtCreate":1662115915787,"gmtModify":1663258027146,"authorId":3573374991554107,"author":{"id":3573374991554107,"idStr":"3573374991554107","authorId":3573374991554107,"name":"sinoob","avatar":"https://static.tigerbbs.com/c7aa6e79d10d30e6c542fe5787c2a09d","vip":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":3,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9939289278,"type":1,"supId":0,"prevId":0,"content":"<u>Latest</u>","text":"<u>Latest</u>","html":"<u>Latest</u>"}],"langContent":"EN"},{"id":9939214126,"gmtCreate":1662115035265,"gmtModify":1676537001137,"author":{"id":"3580076354872466","authorId":"3580076354872466","name":"玉树临风英俊","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"3580076354872466","authorIdStr":"3580076354872466"},"htmlText":"👌&nbsp;","listText":"👌&nbsp;","text":"👌","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/9939214126","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":103735240,"gmtCreate":1662117428823,"gmtModify":1663258027043,"authorId":3562791266647459,"author":{"id":3562791266647459,"idStr":"3562791266647459","authorId":3562791266647459,"name":"atsc","avatar":"https://static.tigerbbs.com/9ec47b1c36e59ba1ef8caac8ab619319","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.08.11","exceedPercentage":"93.45%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9939214126,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9939216694,"gmtCreate":1662114476618,"gmtModify":1676537000991,"author":{"id":"3565146699964497","authorId":"3565146699964497","name":"ycwoo","avatar":"https://community-static.tradeup.com/news/2f48b4bbc66c0bf509f7199142c1a2f2","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":2,"crmLevelSwitch":1,"idStr":"3565146699964497","authorIdStr":"3565146699964497"},"htmlText":"Great article! I would like to share it.","listText":"Great article! I would like to share it.","text":"Great article! I would like to share it.","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939216694","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939237497,"gmtCreate":1662113366919,"gmtModify":1676537000667,"author":{"id":"3579412043719168","authorId":"3579412043719168","name":"jerwy","avatar":"https://static.tigerbbs.com/fdc16e3a47a2704d68f0ff55284feb48","vip":1,"hat":"https://static.tigerbbs.com/b0a2963eb37c60c5d6d4a8dbcd266952","crmLevel":4,"crmLevelSwitch":1,"idStr":"3579412043719168","authorIdStr":"3579412043719168"},"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939237497","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939236567,"gmtCreate":1662112400759,"gmtModify":1676537000432,"author":{"id":"4089116574465250","authorId":"4089116574465250","name":"MrHuattt","avatar":"https://community-static.tradeup.com/news/e67f8f8c2b0192fadc4cd499a84e6c8b","vip":1,"crmLevel":5,"crmLevelSwitch":1,"idStr":"4089116574465250","authorIdStr":"4089116574465250"},"htmlText":"Okau","listText":"Okau","text":"Okau","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939236567","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939294433,"gmtCreate":1662110964122,"gmtModify":1676537000120,"author":{"id":"3574334422904887","authorId":"3574334422904887","name":"Mccoy","avatar":"https://community-static.tradeup.com/news/e8056450a938b10bf05b8fbc1f85e39a","vip":1,"crmLevel":8,"crmLevelSwitch":1,"idStr":"3574334422904887","authorIdStr":"3574334422904887"},"htmlText":"Thanks","listText":"Thanks","text":"Thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9939294433","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"EN"},{"id":9939291885,"gmtCreate":1662109466047,"gmtModify":1676536999861,"author":{"id":"3561516256982806","authorId":"3561516256982806","name":"JaneJane","avatar":"https://static.tigerbbs.com/9b18ea76092852ca384c90dd687df5f4","vip":1,"hat":"https://static.tigerbbs.com/b073a07f77dbe6b3bec6b12311fde6bd","crmLevel":8,"crmLevelSwitch":1,"idStr":"3561516256982806","authorIdStr":"3561516256982806"},"htmlText":"👍🏻","listText":"👍🏻","text":"👍🏻","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":4,"repostSize":0,"link":"https://ttm.financial/post/9939291885","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":103734719,"gmtCreate":1662114869830,"gmtModify":1663258365333,"authorId":3577409082356068,"author":{"id":3577409082356068,"idStr":"3577409082356068","authorId":3577409082356068,"name":"babiboo","avatar":"https://static.tigerbbs.com/8be2f9f25874d7f974661428b042a2e7","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9939291885,"type":1,"supId":103734053,"prevId":0,"content":"<u>ohh</u>","text":"<u>ohh</u>","html":"<u>ohh</u>"},{"id":103734381,"gmtCreate":1662113363390,"gmtModify":1663258025031,"authorId":3579412043719168,"author":{"id":3579412043719168,"idStr":"3579412043719168","authorId":3579412043719168,"name":"jerwy","avatar":"https://static.tigerbbs.com/fdc16e3a47a2704d68f0ff55284feb48","vip":1,"currentWearingBadge":{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.12.17","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1001},"crmLevel":4,"crmLevelSwitch":1,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9939291885,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">ok</span>","text":"<span class=\"s1\">ok</span>","html":"<span class=\"s1\">ok</span>"},{"id":103734752,"gmtCreate":1662115051589,"gmtModify":1663258023352,"authorId":3580076354872466,"author":{"id":3580076354872466,"idStr":"3580076354872466","authorId":3580076354872466,"name":"玉树临风英俊","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9939291885,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"},{"id":103734053,"gmtCreate":1662111302395,"gmtModify":1663258022337,"authorId":3570593382729221,"author":{"id":3570593382729221,"idStr":"3570593382729221","authorId":3570593382729221,"name":"Benzz","avatar":"https://static.tigerbbs.com/05492ca80eadb47ced7a52ab97d09507","vip":1,"currentWearingBadge":{"badgeId":"972123088c9646f7b6091ae0662215be-1","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Elite Trader","description":"Total number of securities or futures transactions reached 30","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.96%","individualDisplayEnabled":0,"individualDisplaySort":0,"categoryType":1100},"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9939291885,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"}],"langContent":"EN"},{"id":9939892221,"gmtCreate":1662081828365,"gmtModify":1676536802917,"author":{"id":"4087109808120260","authorId":"4087109808120260","name":"Tanyl","avatar":"https://static.tigerbbs.com/174329973340cf0f5b68791ee5b08afd","vip":1,"crmLevel":9,"crmLevelSwitch":1,"idStr":"4087109808120260","authorIdStr":"4087109808120260"},"htmlText":"Buy Abbott in call option","listText":"Buy Abbott in call option","text":"Buy Abbott in call option","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":7,"commentSize":2,"repostSize":0,"link":"https://ttm.financial/post/9939892221","repostId":2264296558,"repostType":4,"repost":{"id":"2264296558","pubTimestamp":1662107204,"share":"https://ttm.financial/m/news/2264296558?lang=&edition=fundamental","pubTime":"2022-09-02 16:26","market":"us","language":"en","title":"3 Dividend Stocks to Buy in September for Passive Income Generation","url":"https://stock-news.laohu8.com/highlight/detail?id=2264296558","media":"Motley Fool","summary":"Buying these stocks now could lead to dividend payments that grow for the rest of your life.","content":"<html><head></head><body><p>Do you like getting paid to do practically nothing? I thought so.</p><p>Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they&#39;re known for raising their dividend payouts year after year. Here&#39;s how they could provide ever-increasing dividend payments to your brokerage account.</p><h2>1. <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a></h2><p>This healthcare conglomerate&#39;s COVID-19 tests made it a stock market darling in 2021. Shares of <a href=\"https://laohu8.com/S/ABT\">Abbott Laboratories </a> have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.</p><p>In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.</p><p>Declining COVID-19 testing revenue isn&#39;t a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott&#39;s FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.</p><p>Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.</p><h2>2. <a href=\"https://laohu8.com/S/CVS\">CVS Health </a></h2><p>Shares of <a href=\"https://laohu8.com/S/CVS\">CVS Health </a> surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.</p><p>At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.</p><p>Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can&#39;t match, and it isn&#39;t the company&#39;s only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.</p><p>CVS Health&#39;s unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.</p><h2>3. <a href=\"https://laohu8.com/S/ABBV\">AbbVie </a></h2><p><a href=\"https://laohu8.com/S/ABBV\">AbbVie </a> was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.</p><p>Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.</p><p>AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.</p><p>AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Dividend Stocks to Buy in September for Passive Income Generation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Dividend Stocks to Buy in September for Passive Income Generation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-09-02 16:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4568":"美国抗疫概念","CVS":"西维斯健康","BK4581":"高盛持仓","ABT":"雅培","BK4504":"桥水持仓","BK4566":"资本集团","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓","BK4551":"寇图资本持仓","ABBV":"艾伯维公司"},"source_url":"https://www.fool.com/investing/2022/09/01/3-dividend-stocks-to-buy-in-september-for-passive/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2264296558","content_text":"Do you like getting paid to do practically nothing? I thought so.Lots of savvy investors know that they can generate heaps of passive income with dividend-paying stocks. These three businesses are more than just reliable dividend payers; they're known for raising their dividend payouts year after year. Here's how they could provide ever-increasing dividend payments to your brokerage account.1. Abbott Laboratories This healthcare conglomerate's COVID-19 tests made it a stock market darling in 2021. Shares of Abbott Laboratories  have tumbled around 27% since the beginning of 2022 in response to subsiding demand for COVID tests. Now the stock offers a tempting 1.8% dividend yield that could rise significantly in the years ahead.In the second quarter, COVID-19 testing-related sales fell to $2.3 billion from $3.3 billion during the first quarter of 2022. Luckily for long-term investors, the company could report significant earnings growth even if COVID-19 sales fall off a cliff.Declining COVID-19 testing revenue isn't a major issue for this diversified conglomerate because its diabetes-care segment is about to rocket higher. In May, the FDA granted clearance to Abbott's FreeStyle Libre 3 system. This device is only the size of a couple of pennies stacked together, but once a patient sticks it on her or his arm, it monitors blood sugar levels constantly for two weeks.Constant monitoring leads to fewer interventions in expensive hospitals, so insurers and government payers are eager to reimburse patients for the devices. With glucose monitoring sales about to explode higher, Abbott could approve some big dividend raises in the foreseeable future.2. CVS Health Shares of CVS Health  surged late last year when the company announced that it would begin raising its dividend payout again. Since then, the stock has been in a holding pattern.At recent prices, shares of CVS Health offer a 2.2% yield that could grow significantly in the years ahead. In addition to thousands of retail pharmacies, this conglomerate owns a pharmacy benefits management business that boasts more than 110 million plan members.Integrating a pharmacy benefits management business is one advantage its peers in the retail pharmacy space can't match, and it isn't the company's only big advantage. CVS Health previously paused raising its dividend payout to pay off its acquisition of Aetna, a health insurer that currently collects premiums from an estimated 35 million members.CVS Health's unique combination of related businesses allowed the company to raise its dividend payout by 10% this year. Without any competitors combining a large retail footprint with a health benefits management business, the latest big payout bump could be the first of many in the years ahead.3. AbbVie AbbVie  was once the pharmaceutical segment of Abbott Laboratories. Shares of AbbVie offer an above-average yield of 4.2% that could climb even higher.Since the drugmaker spun off in 2013, its dividend has risen an astonishing 253% on the back of its lead drug, Humira. Second-quarter sales of Humira rose 9.6% year over year to a stunning $4.7 billion in the U.S. Unfortunately, international Humira revenue fell 13.8% to $699 million.AbbVie offers an above-average dividend now because U.S. Humira sales will soon go the same way as international sales. An interchangeable biosimilar version of the anti-inflammatory blockbuster became available in the U.S. this July.AbbVie investors can expect their dividend payouts to continue rising in the face of Humira competition because the company has new blockbuster drugs to pick up the slack. Second-quarter sales of Rinvoq, a new arthritis drug, and Skyrizi, a new psoriasis drug, soared 75% year over year to a combined $1.84 billion. With new blockbusters to offset Humira losses, AbbVie shareholders could see more big payout bumps in the years ahead.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":103734034,"gmtCreate":1662111205527,"gmtModify":1663258021329,"authorId":3582030171524236,"author":{"id":3582030171524236,"idStr":"3582030171524236","authorId":3582030171524236,"name":"Stephanie712","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":2,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9939892221,"type":1,"supId":0,"prevId":0,"content":"<span class=\"s1\">Ok</span>","text":"<span class=\"s1\">Ok</span>","html":"<span class=\"s1\">Ok</span>"},{"id":103734074,"gmtCreate":1662111401808,"gmtModify":1663258021246,"authorId":3575885376205492,"author":{"id":3575885376205492,"idStr":"3575885376205492","authorId":3575885376205492,"name":"HUATBIG","avatar":"https://static.tigerbbs.com/8397eb8f39c2aeb8068cd1e778d5c453","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":9939892221,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"EN"}],"hasMoreComments":true,"newsSizeData":{"likeSize":153,"commentSize":23,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}